Englewood, CO – Dragonfly™ Endoscopy Inc. is proud to announce FDA 510(k) clearance of a novel 360° Rotatable Pancreaticobiliary Scope. This first-of-its-kind device features a 10.5Fr catheter, a 1.7mm working channel, and advanced biopsy and lithotripsy capabilities, bringing critical innovation to cholangiopancreatoscopy.
With over 650,000 ERCP procedures performed annually in the U.S., this new technology enhances direct visualization for improved diagnosis and treatment. The company has initiated a limited U.S. launch, with full commercialization expected by mid-2025.
“We are incredibly excited about this milestone and look forward to shaping the future of cholangioscopy and pancreatoscopy,” said Jeremy Starkweather, Co-Founder and CEO.
For more information, visit www.dragonflyendoscopy.com